U.S. Markets closed

Zoetis Inc (ZTS) Q1 2019 Earnings Call Transcript

Motley Fool Transcribers, The Motley Fool
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Zoetis Inc  (NYSE: ZTS)
Q1 2019 Earnings Call
May. 02, 2019, 8:30 a.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Welcome to the First Quarter 2019 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

The presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. The presentation slides can be managed by you, the viewer, it will not be forwarded automatically. In addition, a replay of this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of zoetis.com.

At this time, all participants have been placed in a listen-only mode and the floor will be opened for your questions following the presentation. (Operator Instructions)

It is now my pleasure to turn the floor over to Steve Frank. Steve, you may begin.

Steve Frank -- Vice President of Investor Relations

Thank you. Good morning, everyone, and welcome to the Zoetis first quarter 2019 earnings call. I am joined today by Juan Ramon Alaix, our Chief Executive Officer; and Glenn David, our Chief Financial Officer.

Before we begin, I'll remind you that the slides presented on this call are available on the Investor Relations section of our website and that our remarks today will include forward-looking statements that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and our SEC filings, including, but not limited to, our Annual Report on Form 10-K and our reports on Form 10-Q.

Our remarks today will also include references to certain financial measures, which were not prepared in accordance with Generally Accepted Accounting Principles, or U.S. GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures is included in the financial tables that accompany our earnings press release and in the Company's 8-K filing dated today, May 2nd, 2019. We also cite operational results, which exclude the impact of foreign exchange.

With that, I will turn the call over to Juan Ramon.

Juan Ramon Alaix -- Chief Executive Officer

Thank you, Steve, and good morning, everyone. I will start today by describing some of the dynamics in the animal health industry that are on investors' mind. First is the positive trend for the spending on innovation in companion animal medicines and treatment. Pet owner spending in the U.S. continue to rise in terms of our revenue per visit and number of patient visits. And we also see positive trends for our pet care in the rest of the world. Pet owners are willing to spend the income on medicines and other treatment to ensure a longer and better quality of life for their pets. We believe Zoetis is well positioned to continuing success in the companion animal space as our portfolio of dermatology products, parasiticides and vaccines continue to drive our growth.

Second, we see economic pressures and other challenges continue to impact dairy and cattle producers in the U.S. We still, however, expect to see the U.S. cattle and dairy markets growing for the full year, driven by strong domestic demand for beef and increasingly optimistic outlook for beef and dairy export and a modest improvement in milk prices.

Finally, Africa and Swine fever has made headlines about significant concern for the pork market. It is impacting producers in China with some reports saying that as many as 150 million to 200 million pigs or up to 3% of their annual pork supply could be lost due to the outbreak or context that is more than the U.S. animal pork production. This situation has far reaching implications for the global pork supply chains. The reduction in supply in China is making pigs more valuable, creating opportunities for greater export from other countries and increasing consumption of other products. This situation will evolve through the year and we are monitoring any effect on the overall market and our business, which saw an impact in the first quarter. This type of outbreaks unfortunately are part of doing business in animal health.

This year, we are facing issues with African Swine fever. A few years ago, we dealt with PEDv, with avian flu, and before with Bruton disease. These challenges are why Zoetis has built a diverse portfolio of best-in-class products across all relevant species and geographies to both address opportunities and to manage through economic cycles, disease outbreaks and unfavorable weather conditions.

We communicated in February that we expected the overall industry to grow approximately 5% for the year, excluding the impact of foreign currency. Now, because of African swine fever, we expect the animal health industry to have a lower growth rate in 2019, and we'll continue to assess the broader impact of African swine fever as the year progresses.

Despite some of these temporary challenges, we are maintaining our guidance for operational revenue growth, excluding Abaxis, 4.5% to 6.5% for the full year, which we expect to be faster than the growth of the animal health market.

Turning now to our first quarter results. We are off to a solid start for the year with 11% operational revenue growth being driven by our Companion Animal business. Revenue from the Abaxis acquisition accounted for 5 percentage points of the overall 11% growth. Our sales in companion animal products are once again leading the way with 27% operational growth based on the addition of our sales from Abaxis as well as our parasiticides and key dermatology portfolio.

Our livestock product sales declined 3% operationally due to challenge in certain cattle and swine markets. For the first quarter, we view our adjusted net income by 18% operationally and adjusted diluted EPS by 19% as we benefited from a strong revenue growth and a significant increase in gross margin due to pricing, favorable product mix and cost improvements. Glenn will provide more details on our first quarter performance in his remarks. Our results once again confirm the importance and value for broad and innovative portfolio in the animal health industry, and we remain confident in our performance and outlook for the full year.

Looking ahead, we continue to invest in advancing our pipeline and ensuring successful market launches of new products and further integration of our vaccines for this year. Since our last quarterly earnings announcement, we have seen key companion animal products, including CYTOPOINT and Simparica for dogs, and Revolution Plus for cats continue to gain approvals in markets outside the U.S. Our Core EQ Innovator, the first and only combination vaccine to offer protection against five core equine diseases was also approved in Canada. On that week, Zoetis received approval of Apoquel in China, one of Zoetis' largest companion animal market, and we expect to launch the product there within the next three months.

On the livestock side, we launched Clarified Plus for Jersey cattle in the U.S. This is the first genomic test for this breed that provides a direct indication about the genetic risk factors for seven of the most common and costly adult cattle diseases. In terms of our R&D pipeline, we still anticipate launching this year an new injector parasiticide formulation to protect dogs against heartworm for up to 12 months pending FDA approval.

Our new three-way combination parasiticides composed of Simparica and two other active ingredients still in regulatory review in the U.S. and that with the European Medicines Agency. Reviews are also under way in Canada and Brazil with part of the submission expected in Japan, China and Australia regions. If approved, we anticipate this product coming to market in the 2020.

We will also continue working on new monoclonal antibodies to manage pain in dogs and cats and dermatology for cats. Those programs are progressing and we'll keep investors informed of future finding in this area. We feel very positive about the benefits these settlements can provide to greater compliance, convenience and efficacy for different species.

In the case of other research for livestock, I would point to our programs in vector vaccine technology for our poultry. Research into promising new classes of antibiotics and our ongoing investments in diagnostics, genetics, devices, digital and data analytics technologies that can be used in applications like precision livestock farming.

Additionally, we have vaccine programs to address current and future emerging diseases, which has been a growth driver for our industry in the past. We also maintain a comprehensive portfolio of approximately 300 product lines for Zoetis, and we invest significantly each year on lifecycle innovation that keep those products competitive and growing.

Finally, we are making good progress on the integration of Abaxis. We remain positive on the point-of-care diagnostic market. Given its a stronger global growth prospects as well as the critical role these diagnostics play in the pet clinics. We are excited about the strength of the Abaxis portfolio and the way our field force is already presenting it to customers around the world. Our U.S. imports have been working to drive greater growth through new lead generation for diagnostics.

In international markets, we have nearly completed staffing and training of our expanding diagnostic, implemented a new customer service model across these markets and view this as a greenfield opportunity for future growth. We are pleased with our progress to-date and we continue to view 2019 as an important year for the integration and platform setting, enhancing certain product and customer experiences and developing more progress essentially for customer solutions that leverage our new diagnostic assets.

Including our first quarter results once again demonstrate the stability and the diversed strength of our portfolio in a dynamic animal health industry. We are executing on our strategies for growth across the continuum of care with new products and solutions that help our customers, predict, prevent, detect and treat diseases in animals while navigating the evolving trends in animal health. And we are investing and making important progress in key areas such as dermatology, but I think besides diagnostic, digital and data analytics, where we see both near and long-term growth opportunities.

Thank you for joining us today, and I will now hand the call over to Glenn. Glenn?

Glenn David -- Executive Vice President and Chief Financial Officer

Thank you, Juan Ramon, and good morning. As Juan Ramon noted, 2019 is off to a solid start. Operational revenue growth was 11% and operational adjusted net income growth was 18%. Reported revenue growth for the first quarter was 7% with a 4% unfavorable impact from foreign exchange, driven primarily by currency depreciation of the Euro and Brazilian real.

Excluding the impact of Abaxis acquisition, operational growth for the quarter was 6%. Included in the 6% growth is 4% price and 2% volume. Volume growth includes contributions from key dermatology of 2% and new products of 1%, which were partially offset by declines in other in-line products of 1%. Companion animal demonstrated continued strength this quarter with legacy Abaxis products, parasiticides and key dermatology products leading the growth with positive contributions from all key markets.

Meanwhile, livestock declined in the quarter based upon declines in sales of Medicaid feed additives and challenges like the African swine fever outbreak in China. Our overall results in the first quarter continued to demonstrate the value of the diversified portfolio with double-digit operational growth despite the declines in swine and cattle. Legacy Abaxis products contributed 5% of the Zoetis' operational revenue growth in the quarter with sales of $61 million.

As a reminder, the acquisition of Abaxis was completed in the third quarter of 2018, so sales from legacy Abaxis products are incremental in the first half of 2019. The revenue this quarter represented a decline over the pro forma revenue from the prior year. This decline is primarily driven by new product launches and initial distributor stocking in the first quarter last year. We continue to expect full year growth in diagnostics products as we focus on improving customer experience, connectivity to practice management software and international expansion. Our key dermatology portfolio comprised of APOQUEL and CYTOPOINT, also continued to contribute to growth this quarter with sales of $155 million, a 30% operational increase over the prior year.

New products, including Revolution Plus and Stronghold Plus as it's called internationally. PCV combo vaccines in swine and Core EQ Innovator in equine were also growth drivers in the quarter. Revolution Plus, a topical parasiticide for cats builds upon the sarolaner compound that is found in Simparica. The product launched in the US this quarter and in 2017 internationally and is off to a great start supporting strong growth in the Revolution-Stronghold line in the first quarter.

The decline in other in-line product volume was related to the timing of cattle product purchases in the U.S. African swine fever in China, the divestiture of certain agribusiness products in Japan which occurred in the fourth quarter of 2018 and the implementation of stricter commercial and pricing policies in Brazil. The agribusiness is historically seasonal with a disproportionate sales in the first quarter. These declines were partially offset by the continued strength of Simparica now captured in-line product category, which generated $48 million in global sales this quarter, representing operational growth of 61% over last year.

Now let's discuss the revenue growth by segment for Q1. U.S. revenue grew 13% in the first quarter. Companion animal grew 30% and was partially offset by a 7% decline in livestock. Excluding the impact of Abaxis acquisition, U.S. revenue grew 8%. Companion animal sales in the quarter were driven by sales of legacy Abaxis products, in-line products, including our key dermatology portfolio and Simparica and new products, including Revolutions Plus.

Excluding the impact of the Abaxis acquisition, companion animal growth was 20%. U.S. dermatology sales were $104 million for the quarter, growing 26%, driven by market share gains, price and investments in direct-to-consumer advertising, which continue to expand the market. Simparica sales in the quarter was $25 million, growing 40% over the prior year. U.S. livestock declined 7% driven by cattle and swine. Cattle was impacted by the timing of Medicaid feed additive purchases and they are continuing to face headwinds while producer profitability remained low.

Swine was impacted by the discontinuation of a promotional program for our premium products and the timing of medicated feed additive purchases. The decline in cattle and swine were partially offset by another strong quarter for poultry, driven by growth of alternatives to antibiotics in medicated feed additives. Despite the decline this quarter, we continue to anticipate U.S. livestock will grow for the full year.

Turning now to our International segment. Revenue grew 7% operationally in the first quarter. Companion animal operational growth was 23% while livestock declined 1% operationally. Excluding the impact of the Abaxis acquisition, International revenue grew 5%. Companion animal product growth was driven by continued expansion and uptake of key dermatology products, the addition of legacy Abaxis products, strong Simparica sales and growth in China. Excluding the impact of the Abaxis acquisition, companion animal growth was 18%.

Livestock declines were driven by the impact of African swine fever in China and the divestiture of certain agribusiness products in Japan, which were partially offset by growth in poultry, fish and sheep. The complete quarterly results of our top 11 international markets are provided in the tables included in our earnings release, but I would like to highlight a few items for the quarter. The UK had operational revenue growth of 16% in the quarter with companion animal growing 21% and livestock growing 11%. Companion animal growth was primarily related to legacy Abaxis products and increased sales of key dermatology products and Simparica.

Livestock benefited from increased market share in agricultural vaccine in the quarter. In Australia, sales grew 10% operationally driven by companion animal growth of 15% and livestock growth of 6%. This market benefited from key dermatology, legacy Abaxis products and Simparica and companion animal, while livestock growth was related to key brand performance in cattle.

In Brazil, sales grew 1% operationally driven by companion animal growth of 43%, partially offset by livestock declines of 13%. Companion animal revenue growth in Brazil was driven by parasiticides, primarily Simparica and continued strength of Apoquel. Livestock declines in cattle for Brazil related to the strengthening of our commercial and pricing policies, which impacted short-term results. We anticipate these policy updates will strengthen our long-term opportunity in this market. Overall market dynamics remain positive as was our full year outlook.

Moving on to China, we had a challenging quarter with revenue declining 2% operationally. Livestock declined 28% driven by challenges in swine. African swine fever is having a greater than expected impact as the outbreak has worsened in China, reducing the size of the swine herd. We continue to expect other regions, primarily the EU, Brazil and the U.S., to increase exports to China to meet domestic consumer demand. We also anticipate growth in other proteins, although to a lesser degree. Companion animal remain strong, partially offsetting the livestock decline with operational growth of 38% driven by continued growth of vaccines, parasiticides and an expansion of the field force in China, allowing us to capitalize on this fast-growing market.

As Juan Ramon mentioned, we're also very excited about the launch of Apoquel into this important market. Other emerging and developed markets also continued to perform well this quarter, particularly in companion animal. Summarizing international performance, continued growth of key dermatology products, the addition of legacy Abaxis products and diversity across our portfolio, all contributed to a solid quarter despite challenges in livestock.

Now moving on to the rest of the P&L. Adjusted gross margin of 70.2% increased approximately 270 basis points in the quarter on a reported basis compared to the prior year. The improvement this quarter is primarily related to price, favorable product mix, foreign exchange and unit cost improvements, partially offset by the inclusion of the lower margin legacy Abaxis portfolio. We do anticipate a more normalized gross margin in the second quarter as both price and mix impact will moderate. Total adjusted operating expenses, including the impact of the Abaxis acquisition grew 8% operationally. The increase is primarily related to the acquisition of Abaxis and an increase of certain compensation-related expenses. We are anticipating higher expenses in the second quarter, primarily related to the timing of promotional investments for our key products, the timing of R&D project spend and the Abaxis integration.

We are continuing with direct-to-consumer advertising and promotional campaigns in the U.S. that support our key dermatology and parasiticide products with our highest expenses occurring in Q2 and Q3. The adjusted effective tax rate for the quarter was 18.8%. The increase from the comparable 2018 period is predominantly related to the impact of the global intangible low taxed income or GILTI tax, which is a provision of the U.S. tax reform, is effective for Zoetis in 2019.

Our expectation for the full year adjusted effective tax rate is consistent with initial guidance, which is between 20% and 21%. The favorability in the first quarter is primarily driven by the tax benefits from stock-based compensation. Adjusted net income for the quarter grew 18% operationally through a combination of strong revenue growth, favorability in gross margin and moderated growth in operating expenses. Adjusted diluted EPS grew 19% operationally in the quarter versus the same period of 2018.

Now moving on to guidance for the full year. Beginning with revenue, we are decreasing both the low end and high end of the range by $75 million to reflect the impact of foreign exchange. As I noted on the fourth quarter call, U.S. dollar strengthening was something we will be monitoring, and additional USD strengthening has occurred since we set guidance. We are now projecting revenue between $6.1 billion and $6.225 billion while maintaining operational revenue growth of 7.5% to 9.5% over 2018. Our organic operational revenue growth, which excludes the impact of the Abaxis acquisition, is projected to be between 4.5% and 6.5%, consistent with the guidance provided in February. Adjusted cost of sales as a percent of revenue is still expected to be in the range of 31% to 32%.

As I noted earlier, there were some favorable drivers in the first quarter that we expect to moderate through the remainder of the year. We are decreasing the low and high-ends of the range for adjusted SG&A for the year to be between $1.45 billion and $1.5 billion due to the impact of foreign exchange.

Moving on to R&D. We expect 2019 expenses to be between $445 million and $465 million, consistent with the guidance provided in February. Full year adjusted interest and other income deductions is now expected to be approximately $200 million compared to the previous estimate of $220 million. The favorability is largely driven by a reduction in interest expense. Our adjusted effective tax rate for 2019 is expected to be within the range of 20% to 21%, consistent with previous guidance, and we are still projecting adjusted net income in the range of $1.65 billion to $1.7 billion, maintaining 8% to 11% operational growth.

With a more limited foreign exchange impact on the bottom line as well as the benefits of the actions we've taken to reduce interest expense, we continue to expect adjusted diluted EPS to be in the range of $3.42 to $3.52, consistent with previous guidance. Our range for reported diluted EPS of $2.79 -- $2.93, however, is a reduction of both the low and high-ends of the range based upon increased certain significant items, primarily due to a change in estimate related to inventory costing impacting the first quarter.

Finally, I'd like to remind you that our quarterly results may fluctuate and our focus continues to be on the full year. As I've already noted, we anticipate lower gross margin and higher operating expense in the second quarter, which will impact adjusted EPS. The full year impact of the Abaxis acquisition will also continue to have a disproportionate impact on the P&L until we pass the acquisition date in the middle of the third quarter. Finally, foreign exchange will continue to negatively impact the P&L in the second quarter with an impact of approximately 300 basis points to revenue growth.

Now to summarize before we move to Q&A. Our first quarter results continue to demonstrate the value of our geographic and product diversity with operational revenue growth of 11% and operational adjusted net income growth of 18%. We continue to see strength in our companion animal portfolio to drive the year's results and expect growth in livestock for the full year. And we remain committed to delivering on our full-year operational growth rate for revenue and adjusted net income, demonstrating the durability and consistency of our business.

Now, I'll hand things over to the operator to open the line for your questions. Operator?

Questions and Answers:

Operator

(Operator Instructions) We'll take our first question from Erin Wright with Credit Suisse. Please go ahead. Your line is open.

Erin Wright -- Credit Suisse -- Analyst

Can you discuss a little bit how the Abaxis integration is progressing here relative to your internal expectations? It was a little lighter than what we thought in our Abaxis model and is that just the distributor dynamic, and I noticed that the GAAP acquisition related cost takes a little bit higher, is that all attributable to Abaxis and where we stand with it as the key implementation?

And then the second question is on international livestock, just given some of these dynamics around African swine fever and what you called out in Brazil, can you speak to how we should think about that quarterly progression over the course of the year? Thanks.

Juan Ramon Alaix -- Chief Executive Officer

Thank you, Erin. Let me answer the question on Abaxis, and let me first say that we are pleased with the progress that we're making with the integration of Abaxis. The team in the U.S. is already working well, maybe not fully integrating the two portfolios because we mentioned that these have full integration, we need also to work with the integration of SAP. And related to the implementation of SAP for Abaxis, we have decided to move the implementation from August-September to February, because we want our IT team to focus on working on the connectivity of all equipment of Abaxis.

We think that this connectivity that we expect to penalize by the end of the year will help us really to have that much more supported to diagnostics and offer full integration or full connectivity of the diagnostic equipment to the practice management system. We are also pleased with the progress that we are making in International markets. We have now almost completed all the hiring process for reps and also for technical support. We have also said the customer service that would help in really to provide the support to diagnostic customers.

So, in general, we are progressing very well. We continue -- very excited about the quality of the portfolio of Abaxis, and we are very confident that Abaxis will represent a significant growth opportunity, especially from 2020. Now we see 2020 -- 2019 as a year where we are integrating, we are fixing some of the things that we have to identify from the previews Abaxis model, and we are very confident that the projections that we have for this portfolio will be very positive.

In terms of the international livestock, let me provide a comment on Brazil and then I will ask Glenn to go into more details on what we expect for the rest of the year in the total livestock performance. In Brazil, we see that the market that continue growing very fast. It's a very strong growth for Zoetis, so the growth in companion animal is above market growth, so we are growing very fast.

In cattle, we decided to change some of our commercial policies, including prices, and we saw as expected some negative reaction from distribution. This had an impact in the first quarter for Brazil, especially in cattle, but we are convinced that these changes will help us in generating better future growth and improve the profitability of our cattle operations in Brazil. So we remain very convinced that Brazil will be a growth driver for Zoetis, and we are investing to support this growth on that.

Glenn, do you mind to provide more details on the International livestock?

Glenn David -- Executive Vice President and Chief Financial Officer

Absolutely. Erin, just also to your question on Abaxis and the Q1 performance you referenced, distributor stocking. So far, we talked about the performance in Q1 2019 to Q1 2018. In Q1 2018, there was stocking with the introduction of the new products in terms your settlement analyzer and Apoquel rapid test, that did pose a challenging comp between Q1 2019 and Q1 2018.

In terms of the international livestock performance, as Juan Ramon said, for livestock internationally we declined about 1% this quarter, driven by the factors that we discussed in terms of African swine fever as well as the impact in Brazil. We would expect to return to growth in Q2, and that growth to accelerate in Q3 and Q4.

Juan Ramon Alaix -- Chief Executive Officer

Thank you, Glenn. Next question, please.

Operator

We'll go next to Louise Chen with Cantor Fitzgerald. Please go ahead.

Louise Chen -- Cantor Fitzgerald -- Analyst

Hi. Thanks for taking my question here. So I wanted to ask you about your temporary weakness in livestock and when do you expect that to subside this year and then return to growth, and how much of that is macro versus company specific? And then maybe just if you could talk a little bit more about this MSA buyer pattern? Thank you.

Juan Ramon Alaix -- Chief Executive Officer

Well, as we said that in the first quarter, we faced two impacts in terms of the temporary weakness in livestock. One was the cattle business in the U.S. was affected by different factors. And talking about the market, the market declined. We saw that the movement of animals was below expectations. In many cases, driven by weather conditions, but we are optimistic about the cattle business in the U.S. moving forward, the demand for beef is positive, and also the exports are increasing.

Additionally, we expect also in the second half of the year a small increase on the price of the milk also that will help the total cattle business in the U.S.. As many times we mentioned, I think it is difficult to analyze our business in a quarterly basis. There are fluctuations based on buying patterns and promotional activities weather conditions that maybe it's important to understand the business on a yearly basis. We remain confident that the livestock market will be growing at the end of the year. What we are expecting is that the poultry will be growing in line or slightly ahead of the market.

In terms of swine, we expect going lower than the market, and mainly because of the African swine fever. But we expect having a temporary impact, but maybe from a third or fourth quarter and definitely in 2020, we expect a significant recovery because many markets outside of China will expand the production that will generate a significant growth.

And finally, with the cattle, we also expect that for the year overall growing -- we expect growing in the U.S., we expect also growing international markets, but growing below expected market growth.

Glenn David -- Executive Vice President and Chief Financial Officer

And in terms of the timing of the MSA purchases in the U.S., that's really related to the timing of our annual price increases. So, in 2019, we align the timing of our MSA price increases to be in sync with the rest of our portfolio, which is in January, that led to some additional sales in Q4 of 2018 that then destocked in Q1 of 2019. So that is not an impact that we would expect to see as we move forward through the rest of the year.

Juan Ramon Alaix -- Chief Executive Officer

Next question, please.

Operator

We'll go next to Kevin Ellich with Craig-Hallum. Please go ahead.

Kevin Ellich -- Craig-Hallum -- Analyst

Good morning. Hey, Juan Ramon. Just have a couple of questions here. Companion animal continues to be really strong. You're seeing really good growth out of obviously the dermatology portfolio, but also Revolution Plus for cats compared to the dogs, could you talk about what areas you're focused with the product development, maybe more on the feline side in the areas that are being medicalized. Also timing for the monoclonal antibody products.

And then Glenn, on the SG&A and operating expenses, clearly there were some favorability this quarter. And you talked about increased spending, DTC campaign in Q2. Could you give us a little bit more color on that? Thank you.

Juan Ramon Alaix -- Chief Executive Officer

Kevin, we see the product portfolio still showing opportunities for growth. We see opportunities for growing the parasiticides now with Revolution Plus. We still see that Simparica continues gaining momentum in the U.S. and also international markets. Apoquel and CYTOPOINT are growing and we expect to continue growing. We expect to continue growing in the U.S. and also expect to continue growing in international markets. And now, we have the addition of Apoquel in China, that also will support this growth. We are also very confident that this growth is steady for the long-term because, as we said, the current portfolio continue growing, but we expect also to introduce Simparica or a combination of products -- three-way products in 2020, that also we expect that to continue generating growth.

In the future, we are not at this point providing any details of when we expect that monoclonal antibodies to be in the market. But definitely we see opportunities in reline with pain. We see opportunities also in feline with dermatology, again with monoclonal antibodies, and always with monoclonal antibodies in dogs for pain. And we are very confident that the R&D machine will continue bringing innovation to the market in companion animals, but also in livestock. We have products for both companion animal and livestock that will support growth in 2020, 2021, also 2022. So we are very confident that we have a pipeline that will maintain growth that will be in line or faster than the market.

And Glenn will respond the question on G&A.

Glenn David -- Executive Vice President and Chief Financial Officer

Kevin, in terms of the operating expenses. So just for the quarter, our operating expenses grew about 8%. If you back out Abaxis, operating expenses grew around 3% compared to our revenue growth of 6%. So, pretty much in line with our overall expectations over an extended period of time. That being said, we did have some favorability in R&D expenses in terms of the timing as well. So as we move through into Q2 and Q3, we'd expect elevated expenses in Q2 and Q3 as that is the time frame in which our DTC promotions, particularly in the U.S. around our dermatology portfolio and Simparica to kick in at a higher level. And we'd also expect some elevated expenses in terms of our R&D as well.

Juan Ramon Alaix -- Chief Executive Officer

Next question, please.

Operator

We'll go next to Michael Ryskin with Bank of America. Please go ahead.

Michael Ryskin -- Bank of America Merrill Lynch -- Analyst

Hi, guys. Thanks for taking the question. A couple -- I want to dig deeper on some of the moving pieces in the quarter both on the livestock markets in the U.S. and internationally. If I sort of go through some of the items you called out African swine fever, the spend, divestment, looking at your revenues by geography, I think I can estimate that ASF may have had a $5 million to $10 million hit in the quarter. The Japan divestment is somewhere in the same ballpark as well. So, I want to get a sense of if that's the right way to think about it, and is that the similar run rate you would expect for ASF going forward? And then the other one would on the U.S. livestock business. You talked a little bit about the distributor relationship in the stocking in 4Q, but just trying to get a sense of the magnitude of that impact in the first quarter versus the rest of the feedlot pressures as well, so we could plan the phase through the course of the year. Thanks.

Juan Ramon Alaix -- Chief Executive Officer

Thank you, Mike. I will make a general comment on the African swine fever. Then Glenn will go to the details of your questions. So, first, the African swine fever definitely is having a significant impact in China, and we also have an impact in our results. We mentioned that probably up to 30% of pigs would be lost on 150 million to 200 million. And as a reference, in the U.S., production is 120 million per year. But it's also true that in China, the market share of multinational company is only 10%, 90% is products sold by local companies. We definitely see a significant issue in China, mainly for the business in China cattle, so we see that the other countries, the U.S., Brazil, European markets will increase significantly the production of pork to meet all the demands of the Chinese consumers that are definitely for a significant period of time. there will be seen a shortfall for producing in China.

And it seems outside of China, we have a significant market share in swine. In the medium and long-term, we see that as an opportunity to generate growth in swine and also maybe an impact in poultry and to a minor extent also to beef. Because in the end, the consumption of animal products in China will remain and export markets will supply products to meet that demand in the markets.

And then Glenn will go through the details of the impact on African swine fever in the quarter and also the Japan agro business and also the U.S. impact of the value.

Glenn David -- Executive Vice President and Chief Financial Officer

So, Mike, specific to your questions, for ASF and Japan, you mentioned the range of $5 million to $10 million. So what I'd say, ASF is probably at the high end of the range for the quarter and Japan is probably at the low end of that range for the quarter. In terms of U.S. livestock, obviously we did have the impact in Q1. It's a little above that $5 million to $10 million range that you referenced with the bigger portion of that being cattle.

Juan Ramon Alaix -- Chief Executive Officer

Thank you, Glenn. Next question, please.

Operator

The next question is from Jon Block with Stifel. Please go ahead.

Jon Block -- Stifel -- Analyst

Pardon me. Thanks guys, good morning. I've got two long ones. Maybe I'll try to break it up if it's OK with you. The first one is triple or Simparica Trio, any updates on how the filing or interaction with the agency is proceeding? and I'm just curious in your ability to fulfill demand in the early days, obviously with Apoquel there were challenges post launch although, I know some of that was sort of the reliance on a third-party manufacturer. So, any color would be helpful. And then I'll ask a quicker follow up. Thanks.

Juan Ramon Alaix -- Chief Executive Officer

Thank you, Jon. And we have provision with the discussions with the FDA. We have completed out all the sections of the filing and it's just now the normal process of question and answers. We are confident that this year it's strong and it will be approved by the FDA, but always something that is not depending on us but on the regulators. But one of the challenges that we discussed in the past is that we needed to demonstrate 100% efficacy on how we have to provide these data. And we are confident that -- probably that will be approved and ready to be launched in 2020. And definitely we try to learn from previous challenge or issues or mistakes, and definitely in the case of the three-way products, we secured enough active ingredients to be ready for launch the product as soon as the product is approved. So are not expecting any challenge in terms of supplying the market all the demand. Next question.

Operator

We'll go next to David Risinger with Morgan Stanley. Please go ahead.

David Risinger -- Morgan Stanley -- Analyst

Thank you very much. So, I have three questions, please. First, with respect to U.S. companion growth this quarter, could you just give us the figure, the percentage ex-Abaxis? Second, how should we model livestock sequentially in the second quarter? I just don't have a good feel for how we should think -- thinking about the livestock business sequentially in 2Q in the U.S. and ex-U.S. And then, one little tidbit, with respect to the revenue guidance reduction of 1%, was that solely related to FX or was there also some modest impact elsewhere? Thank you.

Juan Ramon Alaix -- Chief Executive Officer

Thank you, Dave. And Glenn will cover these three questions.

Glenn David -- Executive Vice President and Chief Financial Officer

Sure. So just in those questions. In terms of our revenue growth excluding Abaxis focused on companion animal, so globally our companion animal business grew 27%. Without Abaxis we still grew extremely strong at 19% globally. In the U.S., the number was -- with Abaxis we grew 30%, excluding Abaxis we grew 20%, and internationally companion animal grew 23%. Without Abaxis, we grew 18%. So really strong organic growth within our U.S. companion business.

As we mentioned earlier, in terms of the livestock growth sequentially, when you look at it globally, we did decline 3% this quarter in terms of livestock business on an operational basis. We do expect to return to growth in Q2, and we expect that growth to accelerate throughout the year. In terms of the guidance, we reduced the guidance for both the low and high end of the range by $75 million, that was purely due to FX. There were significant movements at the time from when we set guidance. When we set guidance back in February, we were using rates as of late January, and when we set guidance now we're using rates as of the end of -- toward the end of April, and that had a significant movement, so the movement was purely due to FX.

Juan Ramon Alaix -- Chief Executive Officer

Thank you. Next question please.

Operator

And we'll take the next question from John Kreger with William Blair. Please go ahead.

Cody Willis -- William Blair -- Analyst

Hi. This is (ph) Cody Willis on for John Kreger. So, just a quick question surrounding the dermatology portfolio. When you just think about like the penetration rates specifically in the U.S. right now, where do you guys kind of think that is? And then when you think about the international growth in the dermatology portfolio for the rest in 2019 and beyond, where do you guys foresee that going?

And then just when you think about them individually, so Apoquel and CYTOPOINT, have they trended -- have they trended well compared to your expectations and are you seeing that's having like a strong preference for one or the other products? Thanks.

Juan Ramon Alaix -- Chief Executive Officer

In terms of penetration for dermatology portfolio, I think it's -- it's about -- in terms of patient, about 59% and it's something that probably -- 63%, sorry, it's the total patient share, which is based on and we still see opportunities first to continue expanding the market and we will be starting now in the second quarter campaign -- detectable tumor campaign. We set two objectives, one it's expanded market. And also second is that to continue building brand equity for Apoquel.

We see also that these investments are also having a positive impact on CYTOPOINT. We expect dermatology portfolio to continue growing. We expect also to grow faster in international markets than in the U.S., but in the U.S., we still see a positive momentum, and how much is the preferential CYTOPOINT or Apoquel? In that respect, I think we leave veterinarians to decide what is the best for their patients, the pets. And we are not trying that to promote Apoquel in favor of CYTOPOINT, and CYTOPOINT in favor of Apoquel. We are covering all the spectrum of needs in terms of treating dermatology issues, itching in dogs, and that we see that there is (inaudible) cannibalization, but also CYTOPOINT has been growing the market and helping us increase this franchise.

Next question please.

Operator

We'll go next to with Kathy Miner with Cowen & Company. Please go ahead.

Kathleen Miner -- Cowen & Company -- Analyst

Thank you. Good morning. I've two questions. First, could you just provide a little more clarification on your comments about the impacts of the African swine fever on Zoetis, and I appreciate that over time there is going to be a greater demand for the proteins or will see other regions pickup some of the supply? Can you just help us understand why that's medium to long-term and why shouldn't we see some of those dynamics sooner, particularly as supply needs to pickup in some other countries?

And my second question is on Apoquel. First, could you give us the breakdown between CYTOPOINT and Apoquel sales of $155 million you gave us before? And also, in Apoquel in China, could you give us a sense of the market size, is it similar to the EU5 or U.S. and is CYTOPOINT also under review in China? Thank you.

Juan Ramon Alaix -- Chief Executive Officer

Thank you for all the questions, Kathy. So let's go back to the African swine fever and the potential impact. We mentioned that we expect that up to 30% of pigs can be blocked because of the African swine fever in China. So, if we translate this 30% to our revenues in -- so we can also estimate that it will be about 30% of our revenues. Although we expect a little bit lower impact because of maybe sophisticated farms are less affected by the African swine fever, then the production of small farms.

We expect that that it will be an immediate impact in terms of the value of the pigs. As a reference, in the last quarter, in the fourth quarter of 2018, producers in the U.S., they were losing $20 per pig, now they making $30 profit per pig. So, the value of the pigs has increasing significantly, and then their willingness to spend and to keep these pig healthy and productive also will increase. So we expect that that will be a positive impact -- an immediate positive impact.

Then, we expect also that the farmers or producers in U.S., Brazil, European Union will increase production. The cycle of the production is six months. But probably we will need to wait six months to see some impact because it will increase the production. And even that if it takes six months from birth to slaughter, I think we can start using products at earlier stage of the animal. So we expect in the third and the fourth quarters of this year having a positive impact in the swine business in Brazil, U.S. and U.S. market.

And moving into the details of Apoquel breakout, Glenn, do you mind answering that? And also probably those projections in China and providing some context.

Glenn David -- Executive Vice President and Chief Financial Officer

Sure. So, in terms of the total derm revenue, we had $155 million in total sales for the quarter with growth of 30%. To the earlier question, in terms of penetration, U.S. had $104 million in sales and international had around $52 million. So, as the similar amount of medicalized dogs in the U.S. is international, we would expect more rapid growth from international greater penetration over time internationally.

The breakout of $155 million between Apoquel and CYTOPOINT, we had $119 million of sales of Apoquel with 22% operational growth, and we had $36 million of sales in CYTOPOINT with 65% operational growth. In terms of Apoquel in China, very excited about the launch of Apoquel in China, China is one of our largest and fastest growing companion animal markets. Just to put in context though, the overall potential market size. So in 2018, Apoquel globally in all of our international markets, including the U,S., have less than $160 million in sales with our top market internationally generating sales of just below $30 million. So that should give some overall context In terms of the potential of Apoquel in any given international large companion animal market.

Juan Ramon Alaix -- Chief Executive Officer

Thank you. Next question please.

Operator

And we'll go next to Chris Schott with JPMorgan. Please go ahead.

Chris Schott -- JPMorgan -- Analyst

Great. Thanks very much. Just two questions, maybe first on Simparica Trio. Just a little bit more color about how were thinking about the launch of these new triples, how quickly they'll be adopted. Should we be thinking about these as products that could have significant year one uptake or is this a more gradual kind of three to five-year process as these roll out?

The second question, I know it's been touched on a little bit, but your companion business, in particular the U.S. companion business were particularly strong in the quarter and above recent trend, just elaborate a little bit more on what you're seeing here, and if there's anything with either one-time related or either kind of year-over-year timing related in terms of the strength we saw this quarter. Just trying to get a sense of how much of this is just really healthy organic kind of underlying growth versus timing issues. Thanks so much.

Juan Ramon Alaix -- Chief Executive Officer

First, starting with the combination of product for parasiticides. Well, their (ph) upsellness , I think we expect their options would be fast and also will depend. If we are number three, number two or number one in the market, but definitely we see a need for the market to combine internal and parasiticides mainly in dogs. And we are confident that we have significant opportunity to generate growth in 2020, 2021 and also 2022, because we think that that is -- this probably will have a long run, and definitely the opportunity is really to generate our growth in companion animal.

And Glenn will talk about the U.S. companion animal growth in the quarter and the trends for the future.

Glenn David -- Executive Vice President and Chief Financial Officer

Yeah. So what I'll take is overall global compatible growth was very strong. When you take out the impact of Abaxis, we grew 19%, 20% in the U.S., 18% internationally. So both segments growing very rapidly in companion animal, and those are driven just by strong underlying dynamics and trends, particularly around the derm portfolio around Simparica and also really strong performance of Revolution Plus. Q1 of '19 was the launch of Revolution Plus in the U.S., it's off to a very successful start. There is some stocking in Q1 of 2019, particularly in the U.S., but still the start that we're seeing in Revolution Plus is very, very encouraging.

Juan Ramon Alaix -- Chief Executive Officer

Thank you, Glenn. Net question please.

Operator

And we'll go next to Greg Fraser with SunTrust. Please go ahead.

Greg Fraser -- SunTrust Robinson Humphrey -- Analyst

Great. Thanks for taking the questions. This is Greg Fraser on for Gregg Gilbert. As (inaudible) that as livestock business was impacted by destocking related consolidation in the distributor space, that's something that you've observed, I wasn't sure your comment on distributor purchasing patterns which related to what they described, and just a quick follow-up on the livestock commentary, are you anticipating growth for international for the full year? Thank you.

Juan Ramon Alaix -- Chief Executive Officer

Probably we still have some challenge with distribution in Brazil but not in the U.S. In Brazil, I mentioned that we have these changes in the commercial policies that reviews sales to distribution during the quarter. But as I mentioned, we expect that this will support more quality growth in the future, but no changes in the distribution in the US. So, Glenn, do you want to add comments here?

Glenn David -- Executive Vice President and Chief Financial Officer

No, just to your question on livestock growth for the full year, we still are expecting livestock to grow globally in the U.S. and internationally.

Juan Ramon Alaix -- Chief Executive Officer

Thank you. Next question please.

Operator

We will take today's final question from Navin Jacob with UBS. Please go ahead.

Prakhar Agrawal -- UBS -- Analyst

Hi. This is Prakhar Agrawal on behalf of many Navin Jacob. Two questions, please. First, on poultry, your growth in poultry products was quite strong. So could you give more color on what is driving that in terms of the near-term trends and anything specific from your product portfolio? And secondly, one of your competitors recently made an acquisition that included some oncology products, so is Zoetis making an R&D investment in oncology and do you think this market is commercially attractive? Thank you.

Juan Ramon Alaix -- Chief Executive Officer

I will ask Glenn to answer the question on poultry and then I will cover the oncology comment -- part of the question.

Glenn David -- Executive Vice President and Chief Financial Officer

So from a poultry perspective, we continue to perform very well in poultry. Overall very solid growth, higher than the rest of our portfolio livestock, and really that's driven by our portfolio of alternative to antibiotics in poultry that we continue to perform very well within the MSA sector. So that's something that's been consistent for us over the last number of quarters and trend that we expect to continue.

Juan Ramon Alaix -- Chief Executive Officer

And on oncology, we have already a product in oncology. She is working well, which is a (inaudible). We launched this product some years ago. We continue assessing the oncology market, then definitely we have some programs -- internal programs related to monoclonal antibody and some of the products such that still oncology is very limited by market although maybe in the future it will be a potential attractive market. But today, it's a quietly with that opportunity.

And I think, that concludes the questions, and thank you very much for joining us today. And as we said, we remain very confident about the outlook for 2019 and we are maintaining our operational growth, and we are also maintaining our target in terms of adjusted net income. Thank you very much for your attendance.

Operator

And this will conclude today's program. Thank for your participation. You may now disconnect.

Duration: 67 minutes

Call participants:

Steve Frank -- Vice President of Investor Relations

Juan Ramon Alaix -- Chief Executive Officer

Glenn David -- Executive Vice President and Chief Financial Officer

Erin Wright -- Credit Suisse -- Analyst

Louise Chen -- Cantor Fitzgerald -- Analyst

Kevin Ellich -- Craig-Hallum -- Analyst

Michael Ryskin -- Bank of America Merrill Lynch -- Analyst

Jon Block -- Stifel -- Analyst

David Risinger -- Morgan Stanley -- Analyst

Cody Willis -- William Blair -- Analyst

Prakhar Agrawal -- UBS -- Analyst

Kathleen Miner -- Cowen & Company -- Analyst

Chris Schott -- JPMorgan -- Analyst

Greg Fraser -- SunTrust Robinson Humphrey -- Analyst

More ZTS analysis

Transcript powered by AlphaStreet

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

More From The Motley Fool

Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.